Palliative radiotherapy for thoracic spine metastases: Dosimetric advantage of three-dimensional conformal plans.

The aim of the present study was to investigate the dosimetric advantages of three-dimensional conformal radiation therapy (3DCRT) for thoracic spine metastases and compare it with conventional two-dimensional (2D) plans. Radiation therapy (RT) planning data of 10 patients with mid-to-low thoracic spine metastases were analyzed. Computed tomography simulation was performed and the planning target volume (PTV), heart, esophagus, lung and spinal cord were contoured. The 3DCRT plan comprised one posteroanterior (PA) field and two posterior oblique fields. The 2D plans used a single PA field or opposed anteroposterior (AP)/PA fields. The prescription dose of radiation was 30 Gy in 10 fractions. All comparisons of the maximum or mean doses to the organs at risk or the PTV, between two of the three RT plans, demonstrated statistically significant differences (P<0.05), with the exception of the mean esophageal doses between the single PA vs. AP/PA (P=0.285) plans. The mean heart doses were 15.0±3.1 Gy in single PA, 17.3±4.3 Gy in AP/PA and 8.5±1.7 Gy using 3DCRT. The median reduction rates using 3DCRT were 38.9% compared with single PA (range, 29.4-58.5%) or 47.5% relative to AP/PA (range, 34.5-67.1%). The mean esophageal doses were 17.9±2.3 Gy in single PA, 18.2±2.2 Gy in AP/PA and 15.3±1.9 Gy in 3DCRT. The median reduction rate using 3DCRT was 12.8% compared with single PA or 15.6% relative to AP/PA. Compared with the single PA or AP/PA 2D plan, 3DCRT reduced the median dose by 13.7 or 1.9% of the maximum spinal cord dose, respectively, and 14.7 or 2.9% of the maximum PTV dose, respectively. The mean lung doses were 2.7±0.7 Gy in single PA, 2.6±0.7 Gy in AP/PA and 5.1±1.0 Gy in 3DCRT. In conclusion, 3DCRT for mid-to-low thoracic spine metastases demonstrated significant dosimetric advantages by reducing the unnecessary irradiation of critical organs, particularly the heart, and by achieving a homogeneous target dose.